Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
The closing price of Citius Oncology Inc (NASDAQ: CTOR) was $1.0 for the day, down -4.76% from the previous closing price of $1.05. In other words, the price has decreased by -$4.76 from its previous closing price. On the day, 0.35 million shares were traded. CTOR stock price reached its highest trading level at $1.02 during the session, while it also had its lowest trading level at $0.95.
Ratios:
Our analysis of CTOR’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 0.11 and its Current Ratio is at 0.56. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.08.
On November 27, 2024, Maxim Group started tracking the stock assigning a Buy rating and target price of $3.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTOR now has a Market Capitalization of 84797848 and an Enterprise Value of 84673048.
Stock Price History:
The Beta on a monthly basis for CTOR is 3.05, which has changed by -0.11764705 over the last 52 weeks, in comparison to a change of 0.17511821 over the same period for the S&P500. Over the past 52 weeks, CTOR has reached a high of $6.19, while it has fallen to a 52-week low of $0.55. The 50-Day Moving Average of the stock is -24.82%, while the 200-Day Moving Average is calculated to be -35.42%.
Shares Statistics:
CTOR traded an average of 458.07K shares per day over the past three months and 768930 shares per day over the past ten days. A total of 83.51M shares are outstanding, with a floating share count of 14.86M. Insiders hold about 82.47% of the company’s shares, while institutions hold 9.86% stake in the company. Shares short for CTOR as of 1765756800 were 650544 with a Short Ratio of 1.42, compared to 1763078400 on 240239. Therefore, it implies a Short% of Shares Outstanding of 650544 and a Short% of Float of 3.47.
Earnings Estimates
The market rating of Citius Oncology Inc (CTOR) is currently shaped by the ongoing analysis conducted by 1.0 analysts closely monitoring its performance.The consensus estimate for the next quarter is -$0.03, with high estimates of -$0.03 and low estimates of -$0.03. Analysts are recommending an EPS of between -$0.14 and -$0.14 for the fiscal current year, implying an average EPS of -$0.14. EPS for the following year is $0.67, with 1.0 analysts recommending between $0.67 and $0.67.
Revenue Estimates
For the next quarter, 1 analysts are estimating revenue of $12.49M. There is a high estimate of $12.49M for the next quarter, whereas the lowest estimate is $12.49M. Based on 1 analysts’ estimates, the company’s revenue will be $118.94M in the next fiscal year. The high estimate is $118.94M and the low estimate is $118.94M.
